{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:32:19Z","timestamp":1793655139695,"version":"4.5.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":2852,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis GmbH, N\u00ef\u00bf\u00bdrnberg, Germany"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1111\/ajt.12952","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T11:58:05Z","timestamp":1418817485000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study"],"prefix":"10.1016","volume":"15","author":[{"given":"K.","family":"Budde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Arns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"W\u00fcthrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"M\u00fchlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Porstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Veit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-M.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.12952_bib1","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/ajt.12952_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.12952_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MNH.0b013e32834b4343","article-title":"Calcineurin inhibitors in kidney transplantation: Friend or foe?","volume":"20","author":"Casey","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/ajt.12952_bib5","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/TP.0b013e3181a76823","article-title":"Cyclosporine withdrawal improves long-term graft survival in renal transplantation","volume":"87","author":"Gallagher","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1432-2277.2008.00751.x","article-title":"Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation","volume":"22","author":"Haller","year":"2009","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.12952_bib7","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12952_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-6143.2006.01658.x","article-title":"Mycophenolate mofetil\/sirolimus compared to other common immunosuppressive regimens in kidney transplantation","volume":"7","author":"Srinivas","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transplant Int"},{"key":"10.1111\/ajt.12952_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/TP.0b013e3181aa7d87","article-title":"Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus","volume":"88","author":"Albano","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin-inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/ajt.12952_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib21","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":"Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study","volume":"12","author":"Budde","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1111\/ajt.12952_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-6143.2005.01140.x","article-title":"Assessing glomerular filtration rate by estimation equations in kidney transplant recipients","volume":"6","author":"Poggio","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-2277.2010.01051.x","article-title":"mTOR inhibition: The learning curve in kidney transplantation","volume":"23","author":"Weir","year":"2010","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.12952_bib29","first-page":"133","article-title":"mTOR inhibitor\/proliferation signal inhibitors: Entering or leaving the field?","volume":"23","author":"Rostaing","year":"2010","journal-title":"J Nephrol"},{"key":"10.1111\/ajt.12952_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"key":"10.1111\/ajt.12952_bib31","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1600-6143.2011.03637.x","article-title":"Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF\u2014Four-year results of the Postconcept study","volume":"11","author":"Lebranchu","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1432-2277.2012.01432.x","article-title":"Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation","volume":"25","author":"Guba","year":"2012","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.12952_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/TP.0b013e31823ffd0e","article-title":"Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors","volume":"93","author":"S\u00e1nchez-Fructuoso","year":"2012","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12952_bib34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1399-0012.2009.01142.x","article-title":"Proteinuria after conversion to sirolimus in kidney transplant recipients: Impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors\/angiotensin-receptor antagonists","volume":"24","author":"Marx","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.12952_bib35","first-page":"152","article-title":"Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria","volume":"21","author":"Diekmann","year":"2008","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.12952_bib36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1600-6143.2005.01020.x","article-title":"Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation","volume":"5","author":"Halimi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transplant Rev"},{"key":"10.1111\/ajt.12952_bib38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib39","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1600-6143.2007.01759.x","article-title":"Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome","volume":"7","author":"McDonald","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib40","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12952_bib41","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2012.04159.x","article-title":"Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients?","volume":"12","author":"Pascual","year":"2012","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.12952","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:06:39Z","timestamp":1761627999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1600613522000892"],"URL":"https:\/\/doi.org\/10.1111\/ajt.12952","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.12952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}